ResMed Inc.'s attractive
financial prospects and the surge in its
stock over the last five years are key aspects. With insider sales by Peter Farrell and others, investing sentiments are mixed. Despite concerns over its valuation, it remains deemed as a growth stock due to solid execution and exceeding earnings and revenue estimates in Q1. Various asset management firms, including
Cerity Partners and
Vinva Investment Management, hold substantial stakes in the company, indicating institutional belief. Remarkably,
Daiwa Securities Group Inc. and the
Dynamic Technology Lab have recently increased their holdings. Notwithstanding, some entities like the
Bank of Montreal and
Bridgewater Associates LP have reduced their stakes. An intriguing aspect is ResMed's unveiling of the 2030 strategy aiming to propel growth, profitability, and foster shareholder returns. This appeals to long-term investors. However, its earnings growth rate has flagged behind shareholder returns so far. It is also to note that ResMed's outlook for future seems promising and the stock is expected to continue its positive trajectory.
Resmed RMD News Analytics from Fri, 26 Apr 2024 07:00:00 GMT to Sat, 30 Nov 2024 08:41:10 GMT -
Rating 7
- Innovation 4
- Information 8
- Rumor -1
